Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

The biotech space is incredibly exciting, given that companies are investing heavily to treat and prevent diseases. In fact, ...

Antennova, a clinical-stage biotech company focused on oncology today announced that it presented the latest data of CD73 ...

Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...

Teos (ITOS) stock is in focus as experimental cancer doublet therapy, developed with GSK, outperformed Jemperliin a mid-stage ...

Shares of Corvus Pharmaceuticals CRVS gained 13.9% on Sept. 10 after the company announced the initiation of a phase III ...

Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. | Merck & ...

Antennova, a clinical-stage biotech company focused on oncology today announced that it will present the latest data of CD73 ...

Andreasson and colleagues have found, using both in vitro and in vivo models, that kynurenine (Kyn) generated by IDO1 ...

Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...

Andreasson and colleagues have found, using both in vitro and in vivo models, that kynurenine (Kyn) generated by IDO1 suppresses glycolytic metabolism in astrocytes, therefore highlighting the ...

Add a description, image, and links to the molecule-driver topic page so that developers can more easily learn about it.